Rhenman & Partners Asset Management’s Astria Therapeutics ATXS Stock Holding History

Rhenman & Partners Asset Management’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-5,179	Closed	-$441K	–	97
2017 Q2	$441K	Hold	5,179	–	–	0.06%	90
2017 Q1	$497K	Buy	5,179 +3,512	+211%	+$484K	0.08%	86
2016 Q4	$361K	Hold	1,667	–	–	0.07%	90
2016 Q3	$616K	Sell	1,667 -4,085	-71%	-$1.08M	0.1%	91
2016 Q2	$1.28M	Hold	5,752	–	–	0.23%	86
2016 Q1	$1.74M	Buy	5,752 +648	+13%	+$223K	0.35%	79
2015 Q4	$2.43M	Buy	5,104 +97	+2%	+$46.5K	0.37%	80
2015 Q3	$2.43M	Buy	5,007 +583	+13%	+$416K	0.39%	69
2015 Q2	$3.24M	Buy	+4,424	New	+$3.34M	0.39%	78

Other funds holding ATXS

SHI

SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

Clarus Ventures Cambridge, Massachusetts $425M AUM 26.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

ARTA

A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

Rhenman & Partners Asset Management's ATXS Position: Q3 2017 in Review

Rhenman & Partners Asset Management sold out of Astria Therapeutics (ATXS) in Q3 2017, closing a stake of 5,179 shares — an estimated $441K sold.

Rhenman & Partners Asset Management first reported a position in ATXS in Q2 2015 and held it in 9 quarters. The position peaked at $3.24M in Q2 2015. 24 funds tracked by Wall St. Rank hold ATXS as of Q3 2017.

Rhenman & Partners Asset Management reported no remaining Astria Therapeutics position as of Q3 2017 after selling out during the quarter.
Rhenman & Partners Asset Management sold 5,179 Astria Therapeutics shares in Q3 2017, an estimated $441K.
Rhenman & Partners Asset Management first reported a position in Astria Therapeutics in Q2 2015 and held it in 9 quarters.
Rhenman & Partners Asset Management's Astria Therapeutics position peaked at $3.24M in Q2 2015.
24 funds tracked by Wall St. Rank held Astria Therapeutics as of Q3 2017.

Based on Rhenman & Partners Asset Management's 13F filing for Q3 2017, filed 13 Oct 2017.